

- TRAPS (tumor necrosis factor- $\alpha$  receptor-associated periodic syndrome), 141, 422, 2213t, 2214–2215
- Trastuzumab  
action and targets of, 102e-4, 102e-5t, 102e-10, 103e-21, 103e-21t  
adverse effects of  
cardiotoxicity, 103e-13, 103e-21, 103e-26, 620t, 621, 1563  
hypersensitivity reaction, 1796, 1798  
for breast cancer, 102e-4, 102e-5t, 102e-10, 528, 529, 529t, 530  
drug interactions of, 103e-13  
for esophageal cancer, 533  
genetic variations in response to, 39t, 41  
for ovarian cancer, 594
- Traube's sign, 411, 1536
- Trauma  
aortic, 289e-3, 1637, 1638  
back pain following, 117  
bile duct, 2084  
cardiac. *See* Cardiac trauma  
cervical spine, 121–122  
chest wall, 51e-2  
head-related. *See* Head injury  
hypothermia in, 478e-1  
pneumothorax in, 1719  
testicular, 2365  
travel-associated, 797
- Traumatic brain injury (TBI). *See* Head injury
- Traumatic shock, 1748t, 1750
- Travel  
to developing countries, health problems during, 793–794, 794f  
by diabetic patient, 799  
by disabled person, 799  
fitness to fly, 794  
food and water precautions during, 796  
gastrointestinal illness during. *See* Travelers' diarrhea  
health advice for, 794  
for health care purposes, 799  
by heart disease patient, 799  
to high altitudes, 476e-5. *See also* High-altitude illness  
by HIV-infected person, 798  
immunizations for, 794–796, 795t  
infectious disease exposure and, 763  
injury during, 797  
by lung disease patient, 799  
malaria prevention during, 796, 796t, 1382–1384, 1383t  
medical kit for, 797  
in pregnancy, 797–798  
problems after return, 800–801f, 800–802, 802t  
sexually transmitted disease and, 797  
by transplant recipient, 929
- Travelers' diarrhea, 796  
after return, 797  
epidemiology of, 266, 855  
etiology of, 266, 797, 855, 855t  
in HIV infection, 798  
in pregnancy, 797  
prevention of, 268, 797, 857  
self-treatment of, 796–797  
treatment of, 856–857, 857t
- Trazodone  
adverse effects of, 64, 2710t  
for depression, 64, 2710t  
for insomnia, 65, 191  
for PTSD, 2712–2713
- Treacher Collins syndrome, 222t
- "Tree-in-bud" pattern, 308e-12f, 1695
- T regulatory cells (T-regs), 377e-2, 1237. *See also* CD4+ T cells
- TREM2 gene mutations, 2601
- Trematodes/trematode infections, 255e-2, 1423  
approach to the patient, 1424  
biliary (hepatic) flukes. *See* Biliary (hepatic) flukes  
blood flukes. *See* Schistosomiasis  
epidemiology of, 1423t  
intestinal flukes. *See* Intestinal flukes  
lung flukes. *See* Lung flukes (*Paragonimus* spp.)  
prevention and control of, 1429  
treatment of, 1428t
- Tremor, 2618  
clinical features of, 2618, 2619t  
essential, 2619  
etiology of, 2619  
in PD, 2618  
treatment of, 2619–2620  
in Wilson's disease, 2625
- Trench fever, 1080–1082, 1081t
- Trench foot (immersion foot), 478e-4
- Trench mouth (Vincent's angina), 231, 233, 236, 238t
- Trypanosoma* spp., 207e-1, 207e-2t, 1132–1133.  
*See also* Trypanematoses
- Trypanosoma pallidum*, 145e-3, 1132–1133, 1137.  
*See also* Syphilis
- Trypanosoma pallidum* particle agglutination (TPPA) test, 1137
- Trypanematoses, 207e-1  
clinical features of, 207e-2f, 207e-1–3  
comparison of, 207e-2t  
control of, 207e-3  
diagnosis of, 207e-3  
epidemiology of, 207e-1, 207e-1f  
treatment of, 207e-3
- Treprostinil, 1659, 1660t, 2164
- TREs (thyroid response elements), 2287, 2287f
- Tretinoin. *See* All-trans-retinoic acid (ATRA)
- TREX1 gene mutations, 2125
- TRH (thyrotropin-releasing hormone), 401e-2, 401e-4
- Triamcinolone, 462e-19, 2234
- Triamterene  
action of, 332e-9  
drug interactions of, 43  
for hypertension, 1623, 1624t  
for hypokalemic periodic paralysis, 462e-17
- Triazolam  
for anxiety disorders, 2711t  
drug interactions of, 246e-3t  
for insomnia, 191  
overdosage/poisoning with, 473e-10t  
pharmacology of, 2711t
- Triazoles, 350
- Tribeč virus, 1308t
- Triceps skinfold thickness, 462
- Trichiasis, 1172
- Trichinella*/trichinellosis, 1410  
clinical features of, 908t, 1410, 1561  
diagnosis of, 245e-3t, 245e-6t, 1410–1411, 1411f  
eosinophilia in, 245e-6t, 765t  
epidemiology of, 765t, 1410  
life cycle of parasite, 1410, 1410f  
pathogenesis of, 1410  
prevention of, 1411  
treatment of, 246e-13, 1411, 1411t
- Trichloroethylene, 2023
- Tricholemmoma, 364t
- Trichomonas vaginalis*, 1409
- Trichomonas vaginalis* infections, 1409  
clinical features of, 1409  
diagnosis of, 150e-6, 873t, 1409  
screening for, 882  
treatment of, 246e-13, 871, 1409  
vaginal, 873t, 874
- Trichophyton*, 349, 350, 1357. *See also* Dermatophytosis
- Trichosporon*, 1356–1357
- Trichostrongylus*/trichostrongyliasis, 1416
- Trichotillomania, 355t
- Trichromat, 197
- Trichrome stain, 245e-1
- Trichuris trichiura*/trichuriasis (whipworm)  
clinical features of, 1414t, 1416  
diagnosis of, 245e-3t, 245e-5t, 765t, 1416  
epidemiology of, 765t  
life cycle of parasite, 1414t, 1416  
treatment of, 1414t, 1416
- Triclabendazole, 246e-3t, 246e-13
- Tricuspid atresia, 1527
- Tricuspid regurgitation, 1548  
clinical features of, 1548  
diagnosis of, 1548  
etiology of, 1547t, 1548  
in mitral valve disease, 1551  
murmur in, 51e-1f, 51e-2, 51e-4–5, 51e-5f, 1448  
in pulmonary hypertension, 1655  
treatment of, 1548–1549, 1549f
- Tricuspid stenosis, 1547  
in carcinoid syndrome, 564  
clinical features of, 1443, 1547  
vs. constrictive pericarditis, 1576  
diagnosis of, 1547–1548  
etiology of, 1547, 1547t  
heart sounds/murmur in, 51e-1f, 51e-6, 1449, 1547  
pathophysiology of, 1547  
treatment of, 1548
- Tricuspid valve, Ebstein's anomaly of, 1527
- Tricuspid valve repair, 1552
- Tricyclic antidepressants (TCAs)  
action of, 465e-2  
adverse effects of, 93–94, 2682t, 2710t, 2716  
autonomic overactivity, 2643  
erectile dysfunction, 327  
hypertension, 1617t  
hypothermia, 478e-1  
obesity, 2392  
orthostatic hypotension, 146  
contraindications to, 2716  
for depression, 2710t, 2716, 2716f  
distribution of, 34  
drug interactions of, 34t, 42t, 246e-2t, 2711t  
genetic variations in response to, 39t, 40  
for headache, 109, 111  
for irritable bowel syndrome, 1969, 1970t  
metabolism of, 34t  
for migraine prevention, 2594t  
for narcolepsy, 190  
for nausea and vomiting, 260t, 261  
for neuropathy, 2682t  
overdosage/poisoning with, 269e-17f, 473e-9t, 473e-10t, 473e-13t, 1458f  
for pain, 91t, 93–94, 93t  
pharmacology of, 2716
- Trientine, 2519, 2520, 2520t, 2625
- TRIF, 145e-5
- Trifascicular block, 1455, 1476, 1476t. *See also* Atrioventricular conduction block
- Trifluoperazine, 2722t
- Trifluridine, 215e-3t, 215e-9
- Trigeminal autonomic cephalalgias, 107, 2587t, 2594, 2595t
- Trigeminal nerve  
anatomy of, 2645–2646, 2645f  
disorders of, 215, 2646–2647, 2647t  
examination of, 2538
- Trigeminal neuralgia, 2646  
clinical features of, 2646  
differential diagnosis of, 2646  
incidence of, 2646  
in MS, 2664  
oral pain in, 237  
with paroxysmal hemicrania, 2596  
pathophysiology of, 2646  
treatment of, 94, 2646
- Trigeminal neuropathy, 2646–2647
- Trigeminovascular system, 107
- Trigger(s), migraine, 2586
- Trigger point injections, 120
- Triglycerides  
elevated levels of, 2439–2440, 2440t, 2453–2454  
impaired lipolysis of. *See* Lipoprotein disorders  
long-chain, 1935t, 1936  
medium-chain, 1936  
in NALFD, 2055  
in specialized nutritional support formulas, 98e-5
- Trihexyphenidyl, 2615, 2621, 2722